Most lung adenocarcinomas harbor mutations in KRAS gene (32%) and epidermal growth factor receptor (EGFR) (11%), resulting in overactivation of the RAS-RAF-MEK-ERK pathway [3,4]. Here, EGFR is linked to lung adenocarcinoma.